Special Issue Antiviral Drugs 2021

Message from the Guest Editor

The field of antiviral drug discovery has been involved in an unprecedented endeavor to enhance established antiviral strategies and develop novel and innovative approaches for new classes of antiviral agents targeting different life cycle pathways that are critical for the virus, including viral and host factors and new antiviral modalities. In the present Special Issue entitled "Antiviral Drugs", we are inviting the submission of original research articles, letters, and/or reviews from academia, research institutes, not-for-profit organizations, or industry that work on the identification, synthesis, and evaluation of direct-acting antiviral or host-targeting agents that inhibit viral replication or pathogenesis. Furthermore, we also welcome the submission of mechanistic studies of new small organic molecules, metal complexes, and natural products, as well as studies on drug resistance, the in silico design of antiviral agents, and antiviral target validation. Prof. Dr. Grigoris Zoidis

Guest Editor

Dr. Grigoris Zoidis Division of Pharmaceutical Chemistry, Department of Pharmacy, Panepistimiopolis Zografou, 15771 Athens, Greece

Deadline for manuscript submissions

closed (30 November 2022)



Pharmaceuticals

an Open Access Journal by MDPI

Impact Factor 4.3 CiteScore 6.1 Indexed in PubMed



mdpi.com/si/86136

Pharmaceuticals MDPI, Grosspeteranlage 5 4052 Basel, Switzerland Tel: +41 61 683 77 34 pharmaceuticals@mdpi.com

mdpi.com/journal/ pharmaceuticals





Pharmaceuticals

an Open Access Journal by MDPI

Impact Factor 4.3 CiteScore 6.1 Indexed in PubMed





About the Journal

Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*. *Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals* soon.

Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Ciências, Universidade de Lisboa, Lisboa, Portugal

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q2 (Pharmaceutical Science)